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THE IMPLICATIONS OF OCCULT URINARY TRACT INFECTION IN MS 
Hypothesis / aims of study 
Over 75% of MS patients describe lower urinary tract symptoms (LUTS) [1]. We have reported frequent urinary tract infection 
(UTI) which was missed by routine methods of urinalysis in these patients [2]. Whilst the diagnostic thresholds employed in 
routine microbiological practice render standard laboratory urine culture insensitive, even those samples reported as positive 
are frequently dismissed as asymptomatic bacteriuria (ABU) in the absence of acute frequency-dysuria; the notion that UTI is 
ubiquitously associated with acute symptoms is not grounded in evidence. Consequently, the generation of LUTS in patients 
with MS is attributed almost universally to neuropathology, confounded by the performance of current diagnostics, assumptions 
about the nature of infective symptoms, and the expectation of bacteriuria associated with catheter use.  
The key question is whether these patients would benefit from antimicrobial treatment, or whether the occurrence of bacteriuria, 
irrespective of quantitative microbiological constructs, is simply an epiphenomenon associated with the MS bladder. We present 
preliminary data from a prospective study examining the effects of antibiotic treatment in these patients. 
Study design, materials and methods 
This study was prospective, blinded, observational cohort study including patients with MS and OAB symptoms, and 
asymptomatic control subjects. These preliminary data compare outcomes at baseline and twelve months. MS patients 
provided CSU samples whilst control subjects submitted a clean-catch MSU. All samples were subject to immediate cytological 
analysis for pyuria, culture of the spun urinary sediment, and routine laboratory culture. 
A single blinded clinician treated patients with empirical antimicrobial therapy based on clinical assessment and urine 
microscopy findings, without access to study culture data. Treatment was continued until microscopy demonstrated clearance of 
pyuria, and patients reported maximal symptom control defined by a sustained symptom nadir. Symptom and QoL data were 
assessed using ICIQ measures and a patient-reported improvement scale. IBM SPSS 21 (IBM, New York) was used to conduct 
the analysis and the data presented using standard descriptive statistics. SPSS Sample Power was used to determine sample 
sizes. 
Results 
Fifteen patients with MS and OAB (F=13; M=2; mean age=53.5; SD=10.6y) and 15 asymptomatic control subjects (matched for 
age, sex, BMI, and menopausal status) were included in the analysis. All patients had chronic symptoms (minimum duration s ix 
years) and did not demonstrate acute frequency-dysuria. Seventy percent of patients demonstrated a negative routine culture at 
baseline. Between baseline and twelve months, antimicrobial treatment was associated with a reduction in bacterial growth 
(Wilcoxon Z=-3.464; p<0.001) and microscopic pyuria (Wilcoxon Z=-3.43; p<0.001). Median duration of antimicrobial treatment 
was 4.6 months 
Patients demonstrated significant improvements in symptoms and QoL (see figures). Ninety-three percent of patients reported a 
marked (n=10) or moderate (n=4) improvement in bladder function. There were no significant changes in any of the measured 
outcomes for control subjects during the follow-up period.  
Figures: Patient scores for ICIQ-LUTS and ICIQ-LUTSqol assessments at baseline and 12 months. 
 
 
Interpretation of results 
These preliminary data suggest that bacterial infection, largely undisclosed by routine culture methods, may contribute to the 
generation of OAB symptoms in patients with MS. Improvements in symptoms and bladder-related quality of life were 
associated with a reduced bacterial load and a reduction in pyuria, an independent marker of urothelial inflammation.  
 
Concluding message 
The relationship between bacterial infection and chronic LUTS associated with MS may need to be re-examined. This treatment 
effect is currently being tested in an RCT. 
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